Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00246662
Recruitment Status : Completed
First Posted : October 31, 2005
Last Update Posted : March 30, 2017
Information provided by (Responsible Party):
Sunesis Pharmaceuticals

Brief Summary:
This study primarily determined the safety and tolerability of escalating doses of vosaroxin (SNS-595) in 2 dose schedules, and assessed the PK profile of vosaroxin and defined a recommended dose regimen for Phase 2 studies. Secondarily the study assessed potential biomarkers and antileukemic activity.

Condition or disease Intervention/treatment Phase
Leukemia, Lymphocytic, Acute Leukemia, Nonlymphocytic, Acute Leukemia, Myeloid, Chronic Myelodysplastic Syndromes Drug: Vosaroxin Phase 1

Detailed Description:
Patients assigned to 1 of 2 schedules (A and B) in cohorts of at least 3 patients received vosaroxin (SNS-595) intravenously (IV) for up to 4 cycles: once weekly (Days 1, 8, 15 in Schedule A) or twice weekly (Days 1, 4, 8, 11 in Schedule B). Dose escalation proceeded independently for Schedule A (18 mg/m2 initially) and Schedule B (9 mg/m2 initially) in the absence of Dose-limiting Toxicity (DLT) based on a modified Fibonacci sequence. The incidence of DLT during Cycle 1 determined the maximum-tolerated dose (MTD) allowing for treatment delays of up to 14 days to resolve clinically significant abnormal laboratory values or related treatment-emergent adverse events (TEAEs) and one dose reduction of 25% in case of above. Patients with stable disease, hematologic improvement, or partial remission with stable blast counts or experiencing clinical benefit in the opinion of the investigator were eligible to receive vosaroxin for up to 4 additional cycles.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 75 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1b Open-Label, Multicenter Clinical Study of the Safety and Activity of Intravenous Administration of SNS-595 in Patients With Advanced Hematologic Malignancies
Study Start Date : November 14, 2005
Actual Primary Completion Date : December 23, 2008
Actual Study Completion Date : April 2009

Arm Intervention/treatment
Experimental: Sch A (18 mg/m2 vosaroxin initially)
Once weekly intravenous on days 1, 8, 15 up to 4 cycles
Drug: Vosaroxin
All patients receive vosaroxin Injection
Other Names:
  • SNS-595
  • Voreloxin
Experimental: Sch B (9 mg/m2 vosaroxin initially)
Twice weekly intravenous administration on days 1, 4, 8, 11 up to 4 cycles
Drug: Vosaroxin
All patients receive vosaroxin Injection
Other Names:
  • SNS-595
  • Voreloxin

Primary Outcome Measures :
  1. Safety and tolerability [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Pharmacokinetic profile [ Time Frame: 6 months ]
  2. Duration of leukemia-free survival [ Time Frame: 6 months ]
  3. Anti-tumor activity [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Able to understand and willing to sign a written informed consent document
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, 0r 2
  • Received less than or equal to 3 induction/re-induction regimens for disease(s) defined by the protocol
  • Must have relapsed or refractory leukemia for which no standard therapies are expected to result in a durable remission; patients who have not received prior treatment who have either refused or, in the opinion of the Investigator, are not able to tolerate, standard therapy may be included.


  • Prior exposure to SNS-595 (vosaroxin)
  • Pregnant or breastfeeding
  • Women of childbearing potential or male partners of women of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards
  • Any evidence of active central nervous system (CNS) leukemia
  • Any evidence of acute or chronic graft-versus-host disease
  • Has active cancer (other than that which is defined by the inclusion criteria for this protocol), except for skin cancer (excluding melanoma)
  • Laboratory values outside normal or reasonable reference range specified by the protocol
  • Liver function and kidney function outside limits specified by the protocol
  • Not yet recovered from side effects of previous cancer therapy
  • Myocardial infarction, cerebrovascular accident/transient ischemic attack (TIA) or thromboembolic event (deep vein thrombosis or pulmonary embolus) within 6 months before the first SNS-595 dose
  • Requires kidney dialysis (hemodialysis or peritoneal)
  • Received an investigational agent within 14 days before Cycle 1, Day 1
  • Prior pelvic radiation therapy or radiation to greater than or equal to 25% of bone marrow reserve (palliative radiation is not excluded as long as it does not exceed greater than or equal to 25% of bone marrow reserve)
  • Any other medical (uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia), psychological, or social condition that, in the opinion of the Principal Investigator, would contraindicate the patient's participation in the clinical trial due to safety or compliance with study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00246662

United States, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612
United States, Indiana
Indiana University Cancer Center
Indianapolis, Indiana, United States, 46202
United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21231
United States, New Mexico
New Mexico Cancer Care Alliance
Albuquerque, New Mexico, United States, 87196
United States, Texas
University of Texas, MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Sunesis Pharmaceuticals
Study Director: Glenn Michelson, MD Sunesis Pharmaceuticals

Responsible Party: Sunesis Pharmaceuticals Identifier: NCT00246662     History of Changes
Other Study ID Numbers: SPO-0004
First Posted: October 31, 2005    Key Record Dates
Last Update Posted: March 30, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Aggregate data of participants experiencing Adverse Events

Keywords provided by Sunesis Pharmaceuticals:
Myelodysplastic Syndromes

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Leukemia, Myeloid
Leukemia, Lymphoid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Myeloproliferative Disorders